A new review maps how cold agglutinin disease is defined by a clonal B-cell disorder and complement-driven hemolysis, and outlines why older approaches like steroids and splenectomy have limited success. The analysis also highlights how sutimlimab and emerging agents are reshaping treatment strategies. For biotech stakeholders, the report underscores the clinical shift toward complement inhibition and the broader trend toward mechanism-specific therapy in rare hematology. It also suggests that pipeline differentiation will depend on duration, breadth of complement coverage, and patient selection. The review’s emphasis on disease biology and treatment response provides a framework for evaluating new entries aiming to build on sutimlimab’s commercial and clinical momentum. While the piece is not a clinical trial update, it offers decision-relevant context for investors tracking next-generation complement modulators.